Janux Therapeutics Inc (JANX)vsRoyalty Pharma Plc (RPRX)
JANX
Janux Therapeutics Inc
$15.85
-1.55%
HEALTHCARE · Cap: $925.13M
RPRX
Royalty Pharma Plc
$56.77
-0.86%
HEALTHCARE · Cap: $33.65B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 17671% more annual revenue ($2.44B vs $13.73M). RPRX leads profitability with a 33.9% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
JANX
Hold40
out of 100
Grade: D
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+81.2%
Fair Value
$69.78
Current Price
$15.85
$53.93 discount
Margin of Safety
-66.8%
Fair Value
$35.03
Current Price
$56.77
$21.74 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 2178.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JANX
The strongest argument for JANX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 2178.0% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : JANX
The primary concerns for JANX are EPS Growth, Market Cap, Profit Margin.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
JANX profiles as a hypergrowth stock while RPRX is a mature play — different risk/reward profiles.
JANX carries more volatility with a beta of 2.51 — expect wider price swings.
JANX is growing revenue faster at 2178.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 40/100), backed by strong 33.9% margins and 11.0% revenue growth. JANX offers better value entry with a 81.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Janux Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?